Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Aurinia Pharmaceuticals Inc. < Previous 1 2 3 Next > Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis November 02, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results November 02, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis October 26, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 October 19, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR) October 13, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital September 21, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines August 21, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results August 03, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023 July 20, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events July 19, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value June 29, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy June 20, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone June 01, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees May 26, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Announces 2023 Annual General Meeting Results May 17, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference May 09, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results May 04, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis May 03, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting May 02, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin) May 02, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys April 25, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023 April 24, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office April 11, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial April 05, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 03, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 06, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates February 28, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference February 24, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023 February 07, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 06, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.